IL-36: a therapeutic target for ulcerative colitis?

References

• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009 Nov 19; 361(21):2066–2078.
   PubMedGoogle Scholar
• Gheorghe C, Pascu O, Gheorghe L, et al. Epidemiology of inflammatory bowel disease in adults who refer to gastroenterology care in Romania: a multicentre study. Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1153–1159.
   PubMedGoogle Scholar
• Jacobsen BA, Fallingborg J, Rasmussen HH, et al. Increase in incidence and prevalence of inflammatory bowel disease in northern Denmark: a population-based study, 1978-2002. Eur J Gastroenterol Hepatol. 2006 Jun;18(6):601–606.
   PubMedGoogle Scholar
• Burisch J, Jess T, Martinato M, et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013 May;7(4):322–337.
   PubMed Web of Science ®Google Scholar
• Cohen RD, Yu AP, Wu EQ, et al. Systematic review: the costs of ulcerative colitis in Western countries. Aliment Pharmacol Ther. 2010 Apr;31(7):693–707.
   PubMed Web of Science ®Google Scholar
• Kirsner JB. Historical aspects of inflammatory bowel disease. J Clin Gastroenterol. 1988 Jun;10(3):286–297.
   PubMedGoogle Scholar
• Actis GC, Pellicano R, Fagoonee S, et al. History of inflammatory bowel diseases. J Clin Med. 2019 Nov 14; 8(11):1970.
   Web of Science ®Google Scholar
• Watkinson G. Sulphasalazine: a review of 40 years’ experience. Drugs. 1986;32(1):1–11.
   PubMedGoogle Scholar
• KIRSNER JB, Palmer WL, Klotz AP. ACTH and cortisone in chronic ulcerative colitis: a comparison of clinical effects. J Lab Clin Med. 1950 Nov;36(5):846.
   PubMedGoogle Scholar
• Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Ther Adv Chronic Dis. 2018 Feb;9(2):65–72.
   PubMed Web of Science ®Google Scholar
• Actis GC, Pellicano R, Ribaldone DG. A concise history of thiopurines for inflammatory bowel disease: from anecdotal reporting to treat-to-target algorithms. Rev Recent Clin Trials. 2019;14(1):4–9.
   PubMed Web of Science ®Google Scholar
• Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust. 1962 Oct 13; 49(2):592–593.
   PubMedGoogle Scholar
• Hauso Ø, Martinsen TC, Waldum H. 5-Aminosalicylic acid, a specific drug for ulcerative colitis. Scand J Gastroenterol. 2015 Aug;50(8):933–941.
   PubMed Web of Science ®Google Scholar
• Actis GC, Pellicano R. Cyclosporine for severe steroid-refractory ulcerative colitis: commenting the comment. Minerva Gastroenterol Dietol. 2018 09;64(3):190–192.
   PubMedGoogle Scholar
• Guan Q, Zhang J. Recent advances: the imbalance of cytokines in the pathogenesis of inflammatory bowel disease. Mediators Inflamm. 2017;2017:4810258.
   PubMed Web of Science ®Google Scholar
• Papamichael K, Rakowsky S, Rivera C, et al. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. Aliment Pharmacol Ther. 2018 02;47(4):478–484.
   PubMed Web of Science ®Google Scholar
• Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun;60(6):780–787.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2014 Jan;1461:85–95. quiz e14-5.
   PubMed Web of Science ®Google Scholar
• Sabino J, Verstockt B, Vermeire S, et al. New biologics and small molecules in inflammatory bowel disease: an update. Therap Adv Gastroenterol. 2019;12:1756284819853208.
   Web of Science ®Google Scholar
• Hanžel J, D’Haens GR. Anti-interleukin-23 agents for the treatment of ulcerative colitis. Expert Opin Biol Ther. 2020 04;20(4):399–406.
   PubMed Web of Science ®Google Scholar
• Fischer A, Zundler S, Atreya R, et al. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut. 2016 10;65(10):1642–1664.
   PubMed Web of Science ®Google Scholar
• Luzentales-Simpson M, Pang YCF, Zhang A, et al. Vedolizumab: potential mechanisms of action for reducing pathological inflammation in inflammatory bowel diseases. Front Cell Dev Biol. 2021;9:612830.
   PubMedGoogle Scholar
• Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013 Aug 22;369(8):699–710.
   PubMed Web of Science ®Google Scholar
• Motoya S, Watanabe K, Ogata H, et al. Vedolizumab in Japanese patients with ulcerative colitis: a phase 3, randomized, double-blind, placebo-controlled study. PLoS One. 2019;14(2):e0212989.
   PubMed Web of Science ®Google Scholar
• Takatsu N, Hisabe T, Higashi D, et al. Vedolizumab in the treatment of ulcerative colitis: an evidence-based review of safety, efficacy, and place of therapy. Core Evid. 2020;15:7–20.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Hart A, Bossuyt P, et al. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2022 02;7(2):128–140.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Lakatos PL, Ritter T, et al. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. Lancet Gastroenterol Hepatol. 2022 01;7(1):28–37.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Siegmund B, Le Berre C, et al. Ulcerative colitis. Nat Rev Dis Primers. 2020;6(1):74.
   PubMed Web of Science ®Google Scholar
• Agrawal M, Verstockt B. Etrolizumab for ulcerative colitis: beyond what meets the eye. Lancet Gastroenterol Hepatol. 2022 01;7(1):2–4.
   PubMedGoogle Scholar
• Rubin DT, Dotan I, DuVall A, et al. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. Lancet Gastroenterol Hepatol. 2022 01;7(1):17–27.
   PubMed Web of Science ®Google Scholar
• Danese S, Colombel JF, Lukas M, et al. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. Lancet Gastroenterol Hepatol. 2022 02;7(2):118–127.
   PubMed Web of Science ®Google Scholar
• Danese S. New therapies for inflammatory bowel disease: from the bench to the bedside. Gut. 2012 Jun;61(6):918–932.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Danese S, Loftus EV, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021 Jun 19;397(10292):2372–2384.
   PubMedGoogle Scholar
• Ribaldone DG, Pellicano R, Vernero M, et al. Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis. Scand J Gastroenterol. 2019 Apr;54(4):407–413.
   PubMed Web of Science ®Google Scholar
• Ahmed W, Galati J, Kumar A, et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021 Mar 31;20(3):e361–e379.
   PubMed Web of Science ®Google Scholar
• Walsh PT, Fallon PG. The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases. Ann N Y Acad Sci. 2018 Apr;1417(1):23–34.
   PubMedGoogle Scholar
• Towne JE, Renshaw BR, Douangpanya J, et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36alpha, IL-36beta, and IL-36gamma) or antagonist (IL-36Ra) activity. J Biol Chem. 2011 Dec 09;286(49):42594–42602.
   PubMedGoogle Scholar
• Clancy DM, Sullivan GP, Moran HBT, et al. Extracellular neutrophil proteases are efficient regulators of IL-1, IL-33, and IL-36 cytokine activity but poor effectors of microbial killing. Cell Rep. 2018;22(11):2937–2950.
   PubMed Web of Science ®Google Scholar
• Henry CM, Sullivan GP, Clancy DM, et al. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines. Cell Rep. 2016 Feb 02; 14(4):708–722.
   PubMedGoogle Scholar
• Bressenot A, Salleron J, Bastien C, et al. Comparing histological activity indexes in UC. Gut. 2015 Sep;64(9):1412–1418.
   PubMed Web of Science ®Google Scholar
• Vergnolle N. Protease inhibition as new therapeutic strategy for GI diseases. Gut. 2016 07;65(7):1215–1224.
   PubMed Web of Science ®Google Scholar
• Cordoro KM, Ucmak D, Hitraya-Low M, et al. Response to Interleukin (IL)-17 inhibition in an adolescent with severe manifestations of IL-36 receptor antagonist deficiency (DITRA). JAMA Dermatol. 2017 Jan 01; 153(1):106–108.
   PubMedGoogle Scholar
• Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011 Aug;365(7):620–628.
   PubMed Web of Science ®Google Scholar
• Onoufriadis A, Simpson MA, Pink AE, et al. Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis. Am J Hum Genet. 2011 Sep;89(3):432–437.
   PubMed Web of Science ®Google Scholar
• Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013 Nov;133(11):2514–2521.
   PubMed Web of Science ®Google Scholar
• Russell SE, Horan RM, Stefanska AM, et al. IL-36α expression is elevated in ulcerative colitis and promotes colonic inflammation. Mucosal Immunol. 2016 09;9(5):1193–1204.
   PubMed Web of Science ®Google Scholar
• Boutet MA, Bart G, Penhoat M, et al. Distinct expression of interleukin (IL)-36alpha, beta and gamma, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and crohn’s disease. Clin Exp Immunol. 2016 May;184(2):159–173.
   PubMed Web of Science ®Google Scholar
• Scheibe K, Backert I, Wirtz S, et al. IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo. Gut. 2017 05;66(5):823–838.
   PubMed Web of Science ®Google Scholar
• Medina-Contreras O, Harusato A, Nishio H, et al. Cutting edge: IL-36 receptor promotes resolution of intestinal damage. J Immunol. 2016 Jan 01;196(1):34–38.
   PubMedGoogle Scholar
• Harusato A, Abo H, Ngo VL, et al. IL-36gamma signaling controls the induced regulatory T cell-Th9 cell balance via NFkappaB activation and STAT transcription factors. Mucosal Immunol. 2017 Mar 22;10(6):1455–1467.
   PubMedGoogle Scholar
• Hovhannisyan Z, Liu N, Khalil-Aguero S, et al. Enhanced IL-36R signaling promotes barrier impairment and inflammation in skin and intestine. Sci Immunol. 2020;5(54). doi:https://doi.org/10.1126/sciimmunol.aax1686.
   Google Scholar
• Ngo VL, Abo H, Maxim E, et al. A cytokine network involving IL-36γ, IL-23, and IL-22 promotes antimicrobial defense and recovery from intestinal barrier damage. Proc Natl Acad Sci U S A. 2018 May;115(22):E5076–E85.
   PubMed Web of Science ®Google Scholar
• Scheibe K, Kersten C, Schmied A, et al. Inhibiting interleukin 36 receptor signaling reduces fibrosis in mice with chronic intestinal inflammation. Gastroenterology. 2019 Nov;156(4):1082–1097.
   PubMed Web of Science ®Google Scholar
• Giannoudaki E, Hernandez-Santana YE, Mulfaul K, et al. Interleukin-36 cytokines alter the intestinal microbiome and can protect against obesity and metabolic dysfunction. Nat Commun. 2019 Sep;10(1):4003.
   PubMed Web of Science ®Google Scholar
• Ungar B, Kopylov U. Advances in the development of new biologics in inflammatory bowel disease. Ann Gastroenterol. 2016;29(3):243–248.
   PubMedGoogle Scholar
• Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the Interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019 03;380(10):981–983.
   PubMed Web of Science ®Google Scholar
• Ingelheim B. NCT03123120: a study in patients with mild or moderate ulcerative colitis who take a TNF inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy. 2017.
   Google Scholar
• Ingelheim B. NCT03648541: BI 655130 Long-term treatment in patients with moderate-to severe ulcerative colitis. Vet Rec. 2018;182(21). doi:https://doi.org/10.1136/vr.k2260
   Google Scholar
• Sullivan GP, Henry CM, Clancy DM, et al. Suppressing IL-36-driven inflammation using peptide pseudosubstrates for neutrophil proteases. Cell Death Dis. 2018 Mar;9(3):378.
   PubMedGoogle Scholar
• Todorović V, Su Z, Putman CB, et al. Small molecule IL-36γ antagonist as a novel therapeutic approach for plaque psoriasis. Sci Rep. 2019;9(1):9089.
   PubMedGoogle Scholar
• Højen JF, Kristensen MLV, McKee AS, et al. IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease. Nat Immunol. 2019 09;20(9):1138–1149.
   PubMed Web of Science ®Google Scholar
• Leon G, Hussey S, Walsh PT. The diverse roles of the IL-36 family in gastrointestinal inflammation and resolution. Inflamm Bowel Dis. 2021;27(3):440–450.
   PubMedGoogle Scholar
• Leon G, Hernandez Santana YE, Irwin N, et al. IIL-36 cytokines imprint a colitogenic phenotype on CD4+ T helper cells. Mucosal Immunol 2022; In Press. 2022 Jan 18th;15(3):491–503.
   Google Scholar
• Smillie CS, Biton M, Ordovas-Montanes J, et al. Intra- and inter-cellular rewiring of the human colon during ulcerative colitis. Cell. 2019;178(3):714–30.e22.
   PubMed Web of Science ®Google Scholar
• Hernández-Santana YE, Leon G, St Leger D, et al. Keratinocyte interleukin-36 receptor expression orchestrates psoriasiform inflammation in mice. Life Sci Alliance. 2020 04;3(4):e201900586.
   PubMedGoogle Scholar
• Goldstein JD, Bassoy EY, Caruso A, et al. IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis. Life Sci Alliance. 2020 06;3(6):e202000688.
   PubMed Web of Science ®Google Scholar
• Nowarski R, Jackson R, Gagliani N, et al. Epithelial IL-18 equilibrium controls barrier function in colitis. Cell. 2015 Dec 3;163(6):1444–1456.
   PubMedGoogle Scholar
• Baum P, Visvanathan S, Garcet S, et al. Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis. J Allergy Clin Immunol. 2022 Apr;149(4):1402–1412.
   PubMed Web of Science ®Google Scholar